Some witnesses have referred to the cost of the manufacturing issue in India and the generics in India and the low cost. Is that part of the reason why we're having a problem making this legislation work, the fact that we're seeing the low-cost generic manufacturers from India actually produce generics lower and more competitively? Is that part of the problem?
On April 23rd, 2007. See this statement in context.